Featured Presentation: Building Alnylam and the Importance of Being Unreasonable

Session details:

Alnylam Pharmaceuticals was founded in 2002 to advance RNAi therapeutics as a whole new class of medicines. Starting from early science, Alnylam succeeded in bringing 6 medicines to patients around the world for both rare and prevalent diseases. New initiatives for RNAi therapeutics include the next generation RNAi platform at City Therapeutics and the leveraging of RNAi for prevention of cardiovascular disease at Corsera Health.